Genetic-Disease Outcome Consortium-Aliskiren Study

Phase 4

Completed

• Conditions: Hypertension with Diabetes Mellitus

• Registration Number: JPRN-UMIN000005612
• Lead Sponsor: GENOMIC DISEASE OUTCOME CONSORTIUM (G-DOC) STUDY INVESTIGATORS

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-05-17
• Study Completion: 2012-12-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Not provided

Exclusion Criteria

1) HbA1c>9% 2) Serum Kalium>5.2mEq/l 3) eGFR<30ml/min/1.73m2 4) Other trial drugs within 30 days 5) Treated with aldosterone blockers or ARB 6) Acute Heart Failure 7) Chronic liver disease, malignant hypertension, stroke, acute coronary syndrome, acute myocardial infarction, PCI or angioplasty within 3 months 8) Pregnancy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Reduction rate of urinary albumin/creatinine ratio (UACR) from baseline after 24 weeks

Secondary Outcome Measures

Name	Time	Method
Remission rate: subjects rate obtaining UACR < 30 mg/gCr Regression rate: subjects rate obtaining UACR ≤ 50% of baseline